A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Russell Schilder
Gynecologic Oncology Group
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Saint Francis Hospital and Medical Center
Hartford, Connecticut, United States
- the Hospital of Central Connecticut
New Britain, Connecticut, United States
- Sarasota Memorial Hospital
Sarasota, Florida, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Indiana University/melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
- Ozark Health Ventures Llc-Cancer Research for the Ozarks Springfield
Springfield, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Stony Brook University Medical Center
Stony Brook, New York, United States
- Carolinas Medical Center
Charlotte, North Carolina, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Tulsa Cancer Institute
Tulsa, Oklahoma, United States
- Abington Memorial Hospital
Abington, Pennsylvania, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Women and Infants Hospital
Providence, Rhode Island, United States
- Anmed Health Cancer Center
Anderson, South Carolina, United States
- Upstate Carolina Ccop
Spartanburg, South Carolina, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
- University of Virginia
Charlottesville, Virginia, United States
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2008
- Primary completion
- 31 Dec 2010
- Completion
- —
- Last update posted
- 15 Apr 2016
- Registered enrollment
- 35
- Registry id
- NCT00671788
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.